Advances in the Adjunctive Treatment of Lennox-Gastaut Syndrome with Clobazam and Cannabidiol

VernacularTitle:氯巴占与大麻二酚辅助治疗Lennox-Gastaut综合征新进展
Author: Jingtian SHI ^{1
,

2} ; Chaoyang CHEN ; Ting YANG ; Ran WEI ; Xuanling ZHANG ; Zining WANG ; Xiaojuan HU ; Ying ZHOU
Author Information

1. 北京大学第一医院药剂科,北京 100034
2. 北京大学第一医院宁夏妇女儿童医院(宁夏回族自治区妇幼保健院)药剂科,银川 750001
Keywords: rare diseases; Lennox-Gastaut syndrome; clobazam; cannabidiol; orplan drugs
From: JOURNAL OF RARE DISEASES 2024;3(2):252-259
CountryChina
Language:Chinese
Abstract: Lennox-Gastaut syndrome(LGS)is a severe,epileptic encephalopathy.In recent years,a variety of drugs have been approved for the treatment of LGS.The U.S.Food and Drug Administration ap-proved clobazam and cannabidiol as adjunctive therapy for LGS in October 2011 and June 2018,respectively.This article provides an overview of clobazam and cannabidiol,including their chemical structures,pharmaco-logical actions,curative effects,safety profile,drug interactions,to introduce the current state of research and the achievements of both drugs.